Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976776 | 0.90 | TAAR1 (0.46) | TAAR1SMN1; SMN2CHRM2PTGS1PTGS2 | |
| SCHEMBL24110191 | 0.89 | LMNA (0.49) | TAAR1SMN1; SMN2CHRM2PTGS1PTGS2 | |
| SCHEMBL777337 | 0.84 | ALDH1A1 (0.56) | TAAR1SMN1; SMN2KMT2AACHETSHR | |
| SCHEMBL29308265 | 0.83 | LMNA (0.44) | TAAR1SMN1; SMN2CHRM2PTGS1PTGS2 | |
| SCHEMBL28473257 | 0.82 | KEAP1 (0.47) | TAAR1SMN1; SMN2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1145830 | 0.82 | TAAR1 (0.48) | TAAR1SMN1; SMN2CHRM2PTGS1PTGS2 | |
| SCHEMBL11275618 | 0.81 | PTGS1 (0.42) | TAAR1SMN1; SMN2CHRM2PTGS1PTGS2 | |
| SCHEMBL20638627 | 0.81 | CHRM2 (0.42) | TAAR1SMN1; SMN2CHRM2PTGS1PTGS2 | |
| SCHEMBL21654563 | 0.80 | TAAR1 (0.46) | TAAR1SMN1; SMN2CHRM2PTGS1PTGS2 | |
| SCHEMBL8757216 | 0.80 | TAAR1 (0.46) | TAAR1SMN1; SMN2CHRM2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116272906-A | Super cross-linked polymer adsorption material containing paired mercapto and preparation method thereof | 哈尔滨工程大学 | 2023-06-23 | — | — | CN | claimed |
| CN-113265155-A | Asphalt tackifier and preparation method thereof | 山东鑫中和新材料科技有限公司 | 2021-08-17 | — | — | CN | claimed |
| CN-120001297-A | Capsule | 宝洁公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-113660926-B | capsule | 宝洁公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-114007734-B | Method for preparing capsules | 宝洁公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-116272906-B | Super cross-linked polymer adsorption material containing paired mercapto and preparation method thereof | 哈尔滨工程大学 | 2024-12-20 | — | — | CN | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| CN-114478326-B | Synthesis method of saflufenacil key intermediate | 安徽宁亿泰科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116272906-A | Super cross-linked polymer adsorption material containing paired mercapto and preparation method thereof | 哈尔滨工程大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-115058289-A | High performance, high impact strength fragrance emitting accord | 国际香料和香精公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-115023148-A | Microencapsulation with plant proteins | 国际香料和香精公司 | 2022-09-06 | — | — | CN | disclosed |
| US-8202997-B2 | Compositions and methods for treating or preventing hypoxic or ischemic injury | IKARIA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202997-B2 | Compositions and methods for treating or preventing hypoxic or ischemic injury | IKARIA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20120070731-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100130555-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | IKARIA, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130555-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | IKARIA, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130555-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | IKARIA, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010045582-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | IKARIA, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130555-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | HIF1AN, HIF1A, HYOU1 | TAAR1 3367/4885SMN1; SMN2 85/4885CHRM2 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.